

Q3 mixed, and Opaganib for COVID-19 disappointing data weighs. We still believe shares significantly undervalued as solid pipeline drives positive valuation. Lowering P/T to \$19.

Q3 results: RedHill recently (on November 30) reported Q3 (ending September) 2021 results. Revenue was \$22 million (+3% y-o-y) and net loss was \$21 million (or EPS of \$(0.46)), compared with our and consensus estimates for revenue of \$23 - 25 million and EPS of \$(0.21) - (0.44). There was no company guidance.

Operating expense: Operating expenses were \$30 million, up \$5 million (y-o-y) as the company scales up its commercial operations and increases R&D.

No guidance: The company declined to provide forward guidance, but reiterated expectation to be breakeven on its commercial operations by Q4 2021.

Lowering estimates: We are lowering our 2021 estimates for revenue to \$87 million, from \$95 million, and for EPS to \$(2.00) from \$(1.95).

Commercialization ramping: RedHill was a clinical stage drug development company that generated no revenue, but this changed quickly since Q2 2020 as it now has 3 Gl drugs for commercialization in the U.S., (Aemcolo, Talicia, Movantik). Movantik had Q3 sales of \$19 million (vs. Q2's \$19 million), with Talicia at \$2 million (vs. Q2's \$2 million). Aemcolo continues to be weighed by low international travels.

COVID-19 data disappointing: In September, RedHill reported Topline data for its global Phase 2/3 study of opaganib in patients with severe COVID-19 pneumonia that did not meet its primary endpoint. A post-hoc analysis of data provides a strong rationale for opaganib's potential efficacy in the underserved hospitalized moderately severe patient group. The company has submitted data packages to the regulatory agencies in the U.S., EU, UK and other territories, for regulatory advice. **Movantik Q3 growth:** In April 2020, RedHill acquired the global rights to Movantik, excluding Europe, Canada and Israel, from AstraZeneca for \$64 million. Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. In Q3, Movantik's quarterly new prescriptions were up 1% from Q2.

TALICIA Q3 growth: In March 2020, TALICIA launched in the U.S. Talicia is the first and only FDA approved rifabutin-based H. pylori therapy and is designed to address the high and growing bacterial resistance and diminished efficacy of clarithromycinbased standard-of-care therapy. H. pylori affects ~35% of U.S. adult and is classified as a Group I carcinogen and is the strongest risk factor for the development of peptic ulcer, gastritis and non-cardia gastric cancer. In Q3, Talicia's quarterly total prescriptions were up 15% from Q2.

Solid pipeline of late-clinical stage drugs: RedHill is still focused on the development of late clinical-stage drugs for inflammatory and gastrointestinal (GI) diseases. The company is pursuing a multiple goal strategy with exclusive rights to 6 late-stage drugs, including 5 in Phase III studies.

RHB-107: In November 2020, the FDA cleared the IND application for Phase 2/3 study for RedHill's second COVID-19 drug, RHB-107 (upamostat), an orally administered novel serine protease inhibitor, with antiviral and potential tissue-protective effects. The U.S. Phase 2/3 study is ongoing (last patient was enrolled in November 2021), with Topline data expected in Q1 2022.

RHB-204 NTM Phase 3: The company has an ongoing (started in November 2020) pivotal Phase 3 clinical study in Nontuberculous Mycobacteria (NTM). RHB-204 is a first-line, stand-alone treatment for pulmonary NTM infections caused by Mycobacterium avium complex (MAC).

Steady balance sheet: Redhill has \$51 million in cash and \$84 million in debt. In its current Q4, Redhill just raised ~\$16 million from stock sales (4.7 million shares at ~\$3.30/share). In November, Redhill entered into a strategic agreement with Kukbo Co. Ltd. to invest \$10 million in Redhill for certain drug rights. We believe it has enough cash through late-2022.

Current valuation very attractive: Maintaining our BUY rating, but lowering our 12month price target to \$19 from \$26. Our P/T is based on a NPV analysis, representing significant upside from current share price. We believe this valuation fairly balances out the high risks with its high growth prospects.

Company Description

Based in Tel Aviv, Israel, RedHill is a biopharmaceutical company focused on the development of late clinical-stage drugs for inflammatory and gastrointestinal (GI) diseases. United States Healthcare

December 24, 2021

Edward Woo, CFA (949) 259-4932 ewoo@ascendiant.com

Stock Data

Exchange:	NasdaqGS
52-week Range:	\$2.46 - 11.52
Shares Outstanding (million):	53
Market cap (\$million):	\$140
EV (\$million):	\$173
Debt (\$million):	\$84
Cash (\$million):	\$51
Avg. Daily Trading Vol. (\$million):	\$3
Float (million shares):	36
Short Interest (million shares):	2
Dividend, annual (yield):	\$0 (NA%)

Revenues (US\$ million)

	<u>2021E</u> (Cur.)	<u>2021E</u> (Old)	<u>2022E</u> (Cur.)	<u>2022E</u> (Old)
Q1 Mar	21A		25E	33E
Q2 Jun	22A		27E	36E
Q3 Sep	22A	23E	29E	38E
Q4 Dec	<u>23E</u>	<u>30E</u>	<u>34E</u>	43E
Total	87E	95E	115E	150E
EV/Revs	2.0x		1.5x	

Earnings per Share (pro forma)

2021E (Cur.) (0.53)A (0.62)A (0.46)A (0.40)E (2.00)E	2021E (Old) (0.44)E (0.36)E (1.95)E	2022E (Cur.) (0.36)E (0.31)E (0.27)E (0.17)E (1.10)E	2022E (Old) (0.24)E (0.19)E (0.12)E (0.02)E (0.57)E
(2.00)E N/A	(1.95)5	N/A	(0.57)E
	(Cur.) (0.53)A (0.62)A (0.46)A (0.40)E (2.00)E	(Cur.) (Old) (0.53)A (0.62)A (0.46)A (0.44)E (0.40)E (0.36)E (2.00)E (1.95)E	(Cur.) (Old) (Cur.) (0.53)A (0.36)E (0.62)A (0.31)E (0.46)A (0.44)E (0.27)E (0.40)E (0.36)E (0.17)E (2.00)E (1.95)E (1.10)E

Important Disclosures

Ascendiant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 18.

COMPANY UPDATE

Rating: BUY

Ticker:	RDHL	
Price:	\$2.64	
Target:		
(fr	om \$26)	





Exhibit 1: RedHill Biopharma Drug Pipeline Stages (as of December 2021)



Emerging U.S. Specialty Pharma: Select Programsⁱ

Commercial Productsⁱⁱ



Talicia® (omeprazole magnesium, amoxicillin and rifabutin) - *H. pylori* infection in adults

Movantik^o (naloxegol) - Opioid induced constipation (OIC) in adults with <u>chronic non-cancer pain</u>



Development Pipeline ^{iv}		Pre-Clinical	Phase 1/2	Phase 3	NDA
RHB-204	NTM disease	Phase 3 U.S. study ongoing			
RHB-104	Crohn's disease	Positive results from Phase 3 MAP US study			
RHB-102	Gastroenteritis	Positive results from Phase 3 U.S. study			
	IBS-D	Positive results from Phase 2	l U.S. study		
RHB-106	Bowel cleanser	Phase 2/3 studies planned			
Opaganib	Oncology Indications + COVID-19	Phase 2/3 COVID-19 & Phase	2 oncology program		
RHB-107 (upamostat)	Oncology/GI + COVID-19	Ongoing Phase 2/3 COVID-1), GI & oncology indications		



Exhibit 2: RedHill Corporate Highlights




Corporate Highlights

An emerging U.S. specialty biopharmaceutical company (Nasdaq: RDHL), primarily focused on U.S. commercialization and development of drugs for gastrointestinal (GI) diseases and infectious diseases

Strong U.S. Commercial Footprint and Robust Development Pipeline with Multiple Near-Term Milestones

Promoting Three FDA-Approved Drugs Multiple Phase 3 and Phase 2 Programs





.

dHill	Q3/2021 Highlights
oharm	اه Financials
Stro	ng quarterly revenues of \$21.6 million
•	Talicia: 15% Q/Q growth in new prescription volume with continued achievement of launch milestones, improving coverage has set stage for potentially strong Q4/2021
•	Movantik: Maintained market leadership position with strong and improved category outlook
Cas	h position: \$51.5 million as of September 30, 2021
	COVID-19 UPDATE IN LIGHT OF OMICRON VARIANT
√ o	paganib Global Phase 2/3 COVID-19 data submitted to several regulatory agencie
	 Novel oral pill addressing moderately severe in-patient/hospitalized population
	 Given its mechanism of action (targeting the host cell), strong potential inhibition of emerging variants of concern, including <u>Omicron variant</u>
	 Opaganib demonstrated a 62% reduction in mortality in a large subpopulation of moderately severe hospitalized COVID-19 patients
	HB-107 (upamostat) – top-line results from Part A of Phase 2/3 in the U.S. and outh Africa expected in Q1/22
	 Novel oral pill addressing non-hospitalized symptomatic patients at early stage of disease
	Recruitment completed for Part A of study
d Hill pharr	Q3/2021 Financial Highlights (1/3)
Re	cord revenues and plan to be near commercial operational breakeven or a quarterly basis by end of 2021 [*]
•	Cash position** of approximately \$51.5 million as of September 30, 2021
•	Post Q3/21 key financings:
	• Strategic investment in RedHill by South Korea's Kukbo Co. of up to \$10 million
	\$15.5 million underwritten public offering
	Net revenues of \$21.6 million in Q3/2021, second consecutive quarter or record net revenues, representing Q/Q growth of 0.5%, attributable to an increase in sales from Talicia® and Movantik®
	Gross profit of \$12.4 million in Q3/2021, representing an improved gross margin of approximately 57%, attributable mainly to reversal of inventory write-off recognized in the third quarter following the FDA approval of

Source: Company reports.

Talicia[®] expiration date extension



Exhibit 4: Opaganib Global Phase 2/3 COVID-19 Study



RedHill

Biopharma

Preliminary Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Pneumonia

Global Phase 2/3 study in patients hospitalized with severe COVID-19 pneumonia

- Randomized, double-blind, parallel-arm, placebo-controlled global Phase 2/3 study
- 475 Patients randomized 1:1 to receive opaganib or placebo on top of standard-of-care
- Primary endpoint: the proportion of patients breathing room air without oxygen support by Day 14

Preliminary top-line data demonstrated positive trends:

 Despite not meeting primary endpoint, analysis of the study efficacy endpoints showed trends in favor of the opaganib arm vs. placebo across multiple endpoints, including the primary endpoint, despite not achieving statistical significance

Post-hoc analysis demonstrated statistically significant benefit to moderately severe patients, supporting potential use in earlier stages of disease:

- Analysis of group of 251 hospitalized, moderately severe COVID-19 patients requiring a Fraction of inspired Oxygen (FiO2) up to 60% (54% of study participants):
 - ✓ 62% statistically significant reduction in mortality (7/117 in opaganib arm vs. 21/134 for placebo; nominal p-value=0.019, Relative Risk 2.6)
 - ✓ 21% statistically significant efficacy benefit in reaching room air by day 14 (77% of opaganib patients vs. 63.5% for placebo; nominal p-value=0.033)
 - ✓ 4 days earlier hospital discharge (10 days for opaganib vs. 14 for placebo) resulting in a total saving of 524 cumulative hospitalization days across the group by Day 42 (nominal p-value=0.0195)
 - ✓ Overall adverse events balanced between the groups, suggesting good safety

Opaganib - COVID-19 Studies

Global Phase 2/3 Study -Potential meaningful benefit to moderately severe patients

Randomized, double-blind, parallel-arm, placebo-controlled global Phase 2/3 study

- 475 subjects enrolled with severe COVID-19 pneumonia; study approved in 10 countries
- While primary endpoint was not achieved, top-line data of study efficacy endpoints showed consistent trends in favor of the opaganib despite not achieving statistical significance
- Post-hoc analysis of 54% of study patients hospitalized with moderately severe disease demonstrated statistically significant reduction in mortality, time to room air and time to hospital discharge
- Data packages submitted to U.S., EU, UK and other regulators ahead of planned regulatory advice

U.S. Phase 2 Study -Positive data announced

U.S. randomized, double-blind, placebocontrolled Phase 2 study

- · Positive top-line safety and efficacy data
- Small sample size of 40 hospitalized patients with COVID-19 pneumonia
- Focused on safety and initial efficacy signals; not powered for statistical significance



Exhibit 5: COVID-19 Opportunities



(omeprazole magnesium, amoxicillin, and rifabutin)

delayed-release capsules

movantik®

(naloxegol) 25 mg toblets

Aemcolo

rifamvcin) delayed



Exhibit 7: Movantik (naloxegol) Acquisition



Movantik Acquisition -A Transformative Event for RedHill




RedHill acquired the global rights to Movantik^{*} (excluding Europe and Canada) from AstraZeneca in April 2020

- RedHill benefits from the large investment made by AstraZeneca to make Movantik a brand leader
 - First oral PAMORA approved in the U.S. for the treatment of OIC
- RedHill is enhancing focus to grow this product
 - Three consecutive quarters of Movantik prescription (TRx) growth led by RedHill promotion, reversing the trend of prescription decline prior to RedHill acquisition
 - RedHill's sales force is enlarging promotional footprint
 - Targeting gastroenterologists, primary care physicians and additional specialists



Continued Best Coverage in PAMORA Class





Movantik Lives Covered

- Best coverage without restrictions in the PAMORA class for both Commercial and Government segments
- 9 out of 10 commercially insured patients can access Movantik
- Improved both Commercial and Medicare Part D coverage YoY since acquiring Movantik
- Continue to identify opportunities to increase or enhance coverage



≪Talicia.


(omeprazole magnesium, arnoxicillin, and rifabutin)

delayed-release capsules

Exhibit 8: TALICIA's H. pylori Infection Market Opportunity

RedHill Biopharma

Talicia[®]- Approved by U.S. FDA for Treatment of *H. pylori* Infection in Adults





Talicia[®]- Clear Clinical Differentiation Provides Large Potential for Market Opportunity in the U.S. and WW



High Prevalence of *H. pylori*

Over 27M treatments annually WWⁱ: U.S.: 2M 5EU: up to 3.2M Japan: up to 1.4M China: up to 4.1M

Diminished Efficacy of Standard-of-Care -Approx. 60%

Growing H. pylori resistance has led to diminished efficacy of current standard-of-care Current Brand Medications Lack Clinical Differentiation

Current brands provide only modest convenience improvement vs. generics

\$4.8B Global Market

Annual U.S. market for *H. pylori* therapies estimated at \$1.4Bⁱ

Talicia®- Potential First-Line Therapy Targeting up to \$1.4B U.S. Market

- Efficacy demonstrated clinical activity with high statistical significance in eradicating H. pylori in U.S. pivotal Phase 3 study
- Addresses concerns of resistance to clarithromycin and metronidazole
- Attractive tolerability profile
- Potential to become preferred first-line treatment
- First all-in-one fixed-dose simple regimen potentially improves compliance and efficacy; Additional protection against generic substitution; Single co-pay



Exhibit 9: Aemcolo Market Opportunity






Launched by RedHill in the U.S. - December 2019

- A rifamycin antibacterial approved by U.S. FDA in Nov. 2018 for the treatment of travelers' diarrhea caused by noninvasive strains of *E. coli* in adults
- In-licensed U.S. rights from Cosmo Pharmaceuticals N.V. in Oct. 2019
- Robust U.S. patent portfolio and FDA QIDP designation, with U.S. marketing exclusivity through 2028
 - ✓ Minimally absorbed
 - ✓ Targeted delivery system
 - Proven efficacy against E. coli
 - ✓ Reliable safety and tolerability
 - Simple BID dosing





Aemcolo: Prepared for International Travel to Return



 Aemcolo Commercial coverage remains greater than 80%

- Almost 50 million people traveled from the U.S. to Mexico and the Caribbean in 2019
- Travel decreased by more than half in 2020 due to pandemic travel restrictions and safety precautions
- Business and leisure travel to higher TD risk countries decreased by almost 60% in 2020



Exhibit 10: RedHill Q3 2021 Commercial Highlights

RedHill Biopharma

Summary

RedHill achieved record Q3/21 prescription volume

117% Talicia® growth over Q3/20

15% Q/Q growth for Talicia[®] and 1.1% for Movantik[®] in Q3/21

73% market share for Movantik[®] – maintaining market leadership in the PAMORA class

RedHill anticipating a strong Q4/21 for both brands



Q4/21 - Commercial Outlook

Continuous Improvement in Execution Established the Foundation for a Strong Q4/21



Movantik®: Focus on volume growth, market growth and additional payor wins




(rifamycin) delayed

market growth and additional payor wins

Talicia®: >15% Q/Q growth in Q3/21; Anticipating accelerated new prescription and prescriber volume growth in Q4/21

Aemcolo®: Non-essential international travel hampered by the COVID-19 pandemic







Movantik Growth Factors:

- ✓ Market access successes with major payors
- Focused RedHill execution in Pain segment
- Favorable opioid prescribing volume trends
- Digital marketing investments to grow the PAMORA market

120,000 110,000 +5.6% +1.1% 100,000

Movantik nTRx Growth - All Channels



Source: Company report

RedHill Biopharma



Exhibit 12: RHB-204 for Pulmonary NTM



RHB-204 - Targeting First-Line Pulmonary NTM Disease

Planned Indication	 Pulmonary Mycobacterium avium Complex (MAC) disease in adults with nodular bronchiectasis
The Product	 Patent-protected, oral all-in-one combination of three antibiotic drugs (clarithromycin, clofazimine and rifabutin) each known to be active against NTM disease caused by MACⁱ
Key Attributes	 Targeting first-line treatment - potential new standard-of-care for a disease with no FDA-approved first-line therapy Convenient stand-alone oral therapy for a chronic disease requiring extended treatment Unique dosing combination - optimizing exposure for safety and efficacy
Market Size	- U.S. market potential estimated at approx. \$530M in 2021 ⁱⁱ
Development Status	 Phase 3 study ongoing QIDP and Fast-Track Designation granted, providing eligibility for rolling NDA review, Priority Review and accelerated approval Orphan Drug designation extends potential U.S. market exclusivity to a tota of 12 years post-approval

Source: Company report.

Exhibit 13: RHB-204 for Pulmonary NTM Pivotal Phase 3 Study



RHB-204 - CleaR-MAC Phase 3 Study Ongoing

A Phase 3 study to assess RHB-204 as a first-line treatment for the Treatment of pulmonary Mycobacterium avium Complex (MAC) disease in adults with nodular bronchiectasis

Study Initiated	- November 2020
	 Multi-center, randomized, double-blind, two-part, placebo-controlled, parallel-group Phase 3 study; 3:2 randomization
	 Up to 40 U.S. clinical sites; potential expansion to UK, Japan and additional territories
Study Design	- Two-part study:
	 Part one: placebo-controlled, subjects evaluated for primary endpoints at Month 6
	 Part two: Open-label treatment with RHB-204 for 10 months, with follow-up 3 months post-treatment
Patient Population	 125 subjects with symptomatic pulmonary MAC disease with nodular bronchiectasis
	- An interim sample size re-estimate is planned at approx. 50% enrolment
	- Co-primary efficacy endpoints for Part one:
	 Sputum culture conversion (SCC) after 6 months of
Endpoints	treatment (consecutive negative sputum cultures at Months 4,5,6)
	 Quality of Life questionnaire – Bronchiectasis (QoL-B) respiratory
	symptoms domain score from Baseline to Month 6 vs. placebo



Exhibit 14: Opaganib (Yeliva) For COVID 19 and Oncology, Gastrointestinal and Inflammatory Diseases



Opaganib - SK2 Inhibitor for COVID-19 and Oncology, Gastrointestinal and Inflammatory Diseases

	The Product	 Potential first-in-class, orally-administered sphingosine kinase-2 (SK2) inhibitor - with anti-cancer, anti-inflammatory activities, targeting multiple oncology, inflammatory and GI indications Potent anti-viral activity, targeting a critical host factor - minimizing potential development of resistance due to viral mutations
	Market	- Significant market potential - multiple indications with an unmet need
		 Completed numerous successful pre-clinical studies in oncology, GI-Inflammation and radioprotection models, as well as food effect and toxicology studies
		 Phase 1 study in cancer patients with advanced solid tumors successfully met primary and secondary endpoints
		- Phase 2a study for treatment of cholangiocarcinoma ongoing
		- Orphan Drug Designation for the treatment of cholangiocarcinoma
	Development Status	- Compassionate use for cholangiocarcinoma under Expanded Access Program
		 Investigator-sponsored Phase 2 study in prostate cancer - Enrollment ongoing in study arm evaluating combination with abiraterone; arm evaluating opaganib in combination with enzalutamide did not meet primary endpoint
		 While Global Phase 2/3 endpoints were not met, a post-hoc analysis showed statistically significant reduction in mortality and reaching room air by Day 14 (primary endpoint) in moderately severe patients
		 Positive top-line safety and efficacy data from U.S. Phase 2 study in patients hospitalized with COVID-19 pneumonia

Source: Company report.

Exhibit 15: RHB-107 For COVID 19 Clinical Trials

Red Biop		RHB-107 - S1 Serine Protease Inhibitor with Ongoing hase 2/3 COVID-19 Study in Non-Hospitalized Patients
		First-in-class, orally-administered inhibitor of S1 family of trypsin-like serine proteases with potential for use in the treatment of cancer, inflammatory lung diseases, irritable bowel syndrome, inflammatory bowel disease and pancreatitis
		RHB-107 is a specific and potent inhibitor of human trypsin-3 (Ki ~ 20nM), trypsin-2 (Ki ~ 75nM), trypsin-6 (~100nM), trypsin-1 (Ki ~ 190nM) and matriptase-1 (~200nM)
	The Drug	RHB-107 also inhibits a specific inhibitor of a number of members of the type II transmembrane serine proteases (TTSPs), some of which are important factors in the spread of infectious disease, including, matriptase, TMPRSS11, HAT-like 5 (HATL5), HAT, TMPRSS2 and hepsin
		Licensed worldwide rights from Heidelberg Pharma (formerly Wilex), excluding China, Taiwan, Macao and Hong Kong
		 Phase 2/3 study in non-hospitalized patients with symptomatic COVID-19 ongoing in U.S. and South Africa; Recruitment completed for part A of the study – top-line data expected Q1/22 with Part B to follow
	Development Status	 Demonstrated clinical safety profile from approx. 200 patients across 10 clinical studies, including Phase 2 studies in locally advanced pancreatic cancer and metastatic breast cancer
		 FDA Orphan Drug Designation awarded for treatment of pancreatic cancer
		 RHB-107 planned to be evaluated in combination with opaganib in an ongoing Phase 2a study in cholangiocarcinoma



RDHL Daily 💳 12/23/21 12 11 10 9 8 7 6 5 4 з 2 Volume 🗕 ©BigCharts.com 10 Millions 5 n 18 19 20 21

Exhibit 16: RedHill Biopharma Ltd. Stock Price (5-year)

Source: https://bigcharts.marketwatch.com/

Exhibit 17: Consensus Expectations (as of 11/30/21)

Revenue (mil)				EPS		
	<u>2021E</u>	<u>2022E</u>		<u>2021E</u>	<u>2022E</u>	
Q1 Mar	\$21A		Q1 Mar	\$(0.53)A		
Q2 Jun	\$22A		Q2 Jun	\$(0.62)A		
Q3 Sep	\$25E		Q3 Sep	\$(0.21)E		
Q4 Dec	\$29E		Q4 Dec	\$(0.20)E		
Total	\$96E	\$144E	Total	\$(1.02)E	\$(0.39)E	

*Quarterly estimates may not add to annual estimates due to variations in contributing estimates and rounding.

Source: Company report, Refinitiv, and Ascendiant Capital Markets estimates



FINANCIAL MODEL

RedHill Biopharma Ltd.

Income Statement (\$ mils) Fiscal Year End: December 31	Mar-19 Q1A	Jun-19 Q2A	Sep-19 Q3A	Dec-19 Q4A	2019 FY-A	Mar-20 Q1A	Jun-20 Q2A	Sep-20 Q3A	Dec-20 Q4A	2020 FY-A	Mar-21 Q1A	Jun-21 Q2A	Sep-21 Q3A	Dec-21 Q4E	2021 FY-E	Mar-22 Q1E	Q2E	Sep-22 Q3E	Dec-22 Q4E	2022 FY-E
License revenue					0.0					0.0					0.0					0.
Product revenue and other	1.7	1.6	1.4	1.6	6.3	1.1	20.9	20.9	21.5	64.4	20.6	21.5	21.6	23.3	87.0	25.0	27.0	29.0	34.0	115.
Total Revenue	1.7	1.6	1.4	1.6	6.3	1.1	20.9	20.9	21.5	64.4	20.6	21.5	21.6	23.3	87.0	25.0	27.0	29.0	34.0	115.
Cost of Revenues	0.4	0.4	0.6	0.8	2.3	1.7	14.2	10.3	10.7	36.9	10.3	10.6	<u>9.2</u>	10.3	40.3	10.0	9.5	8.7	8.5	36.7
Gross Profit	1.3	1.1	0.8	0.8	4.0	(0.7)	6.7	10.6	10.8	27.5	10.3	10.9	12.4	13.0	46.7	15.0	17.6	20.3	25.5	78.4
Research and development	5.4	7.0	2.8	2.3	17.4	2.8	3.2	4.3	6.2	16.5	7.5	10.3	5.8	6.0	29.6	6.5	6.5	6.5	6.5	26.0
Sales and marketing	3.1	4.1	4.9	6.2	18.3	9.0	10.0	13.4	16.9	49.3	13.9	15.2	15.5	15.0	59.7	15.5	15.5	16.0	16.0	63.0
General and administrative	2.0	2.4	2.9	4.1	11.5	4.6	6.0	7.3	7.4	25.4	7.1	10.2	8.4	8.0	33.8	8.0	8.0	8.0	8.0	32.0
Restructuring, litigation, and o		2.4	2.0	4.1	0.0	4.0	0.0	1.0	7.4	0.0	1.1	10.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total operating expenses	10.5	13.5	10.6	12.6	47.2	16.4	19.2	25.1	30.5	91.2	28.5	35.8	29.8	29.0	123.1	30.0	30.0	30.5	30.5	121.0
retai operating expensee	10.0	10.0	10.0	12.0			10.2	20.1	00.0	01.2	20.0	00.0	20.0	20.0	120.1	00.0	00.0	00.0	00.0	
Operating income (loss)	(9.2)	(12.4)	(9.8)	(11.8)	(43.2)	(17.0)	(12.5)	(14.5)	(19.7)	(63.7)	(18.2)	(24.9)	(17.4)	(16.0)	(76.4)	(15.0)	(12.5)	(10.2)	(5.0)	(42.7
Interest income (expense)	(0.7)	1.5	0.0	(0.0)	0.9	(0,1)	(3.5)	(4.2)	(4.6)	(12.5)	(4,7)	(4.2)	(4.0)	(4.0)	(16.9)	(4.0)	(4.0)	(4.0)	(4.0)	(16.0
Other income (expense)	()	(0.1)		0.1	0.0	(2)	(0.0)	()	()	0.0	(,	()	()	()	0.0	(()	()	()	0.0
Income before income taxes	(9.9)	(10.9)	(9.8)	(11.7)	(42.3)	(17.2)	(16.0)	(18.6)	(24.3)	(76.2)	(22.9)	(29.1)	(21.4)	(19.9)	(93.3)	(19.0)	(16.4)	(14.2)	(9.0)	(58.6
Income taxes	()	()	()	(,	0.0	(=)	()	()	(=)	0.0	()	()	()	()	0.0	(,	()	()	()	0.0
Net income (loss)	(9.9)	(10.9)	(9.8)	(11.7)		(17.2)	(16.0)	(18.6)	(24.3)	(76.2)	(22.9)	(29.1)	(21.4)	(19.9)	(93.3)	(19.0)	(16.4)	(14.2)	(9.0)	(58.6
Nonrecurring/noncash adjustme	nts				0.0					0.0					0.0					0.0
Net income (pro forma)	(9.9)	(10.9)	(9.8)	(11.7)	(42.3)	(17.2)	(16.0)	(18.6)	(24.3)	(76.2)	(22.9)	(29.1)	(21.4)	(19.9)	(93.3)	(19.0)	(16.4)	(14.2)	(9.0)	(58.6
EBITDA	(8.4)	(11.2)	(8.8)	(10.8)	(39.2)	(15.9)	(11.5)	(12.3)	(18.2)	(57.8)	(16.8)	(19.1)	(14.7)	(15.4)	(66.0)	(14.4)	(11.9)	(9.6)	(4.4)	(40.3
Shares, Basic	28.4	28.4	28.4	32.6	29.7	35.3	35.8	37.3	37.3	36.4	43.0	46.7	46.8	50.0	46.6	53.0	53.1	53.2	53.3	53.2
Shares, Diluted	28.4	28.4	28.4	32.6	29.7	35.3	35.8	37.3	37.3	36.4	43.0	46.7	46.8	50.0	46.6	53.0	53.1	53.2	53.3	53.2
Shares, Diluted	20.4	20.4	20.4	32.0	29.1	35.5	30.0	31.3	37.3	30.4	43.0	40.7	40.0	50.0	40.0	55.0	55.1	55.2	55.5	55.2
EPS Basic (Pro forma)	(\$0.35)	(\$0.38)	(\$0.35)	(\$0.36)	(\$1.42)	(\$0.49)	(\$0.45)	(\$0.50)	(\$0.65)	(\$2.09)	(\$0.53)	(\$0.62)	(\$0.46)	(\$0.40)	(\$2.00)	(\$0.36)	(\$0.31)	(\$0.27)	(\$0.17)	(\$1.10
EPS Diluted (Pro forma)	(\$0.35)	(\$0.38)	(\$0.35)	(\$0.36)	(\$1.42)	(\$0.49)	(\$0.45)	(\$0.50)	(\$0.65)	(\$2.09)	(\$0.53)	(\$0.62)	(\$0.46)	(\$0.40)	(\$2.00)	(\$0.36)	(\$0.31)	(\$0.27)	(\$0.17)	(\$1.10
Margins																				
Gross margin	76%	73%	55%	50%	64%	-62%	32%	51%	50%	43%	50%	51%	57%	56%	54%	60%	65%	70%	75%	689
Research and development	309%	446%	200%	143%	277%	262%	15%	21%	29%	26%	36%	48%	27%	26%	34%	26%	24%	22%	19%	239
Sales and marketing	181%	265%	349%	387%	291%	853%	48%	64%	79%	77%	68%	71%	72%	64%	69%	62%	57%	55%	47%	559
General and administrative	117%	153%	209%	260%	182%	434%	29%	35%	35%	39%	34%	48%	39%	34%	39%	32%	30%	28%	24%	289
Operating margin	-530%	-792%	-703%	-740%	-687%	-1611%	-60%	-69%	-92%	-99%	-88%	-116%	-81%	-68%	-88%	-60%	-46%	-35%	-15%	-379
Tax rate, GAAP	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	09
Net margin	-568%	-698%	-702%	-735%	-672%	-1625%	-77%	-89%	-113%	-118%	-111%	-135%	-99%	-86%	-107%	-76%	-61%	-49%	-26%	-519
Y/Y % change																				
Total Revenue	-29%	-33%	-36%	17%	-25%	-39%	1237%	1395%	1250%	923%	1848%	3%	3%	9%	35%	22%	26%	34%	46%	329
Gross margin	-29%	-30%	-52%	3%	-23%	-150%	490%	1274%	1230%	581%	-1666%	63%	17%	21%	70%	45%	61%	64%	40 % 95%	689
Research and development	-16%	-30%	-58%	-61%	-21%	-49%	-54%	54%	172%	-5%	171%	221%	35%	-3%	80%	-13%	-37%	12%	8%	-129
Sales and marketing	-1%	33%	-50%	95%	47%	187%	140%	174%	172%	169%	54%	53%	16%	-11%	21%	12%	-37 %	3%	7%	-12
General and administrative	5%	19%	74%		53%	126%	151%	151%	80%	121%	55%	70%	15%	-11%	33%	13%	-22%	-5%	0%	-5
Operating income (loss)	-8%	30%	1%	17%	10%	85%	1%	47%	68%	47%	7%	99%	20%	-19%	20%		-50%	-41%	-69%	-449
Net income (loss)	-1%	-2%	-2%	52%	9%	74%	47%	90%	108%	80%	33%	81%	15%	-18%	23%	-17%	-44%	-34%	-55%	-379
EPS Diluted (Pro forma)	-25%	-26%	-19%	22%	-15%	40%	17%	44%	82%	47%	9%	39%	-9%	-39%	-4%	-33%	-50%	-42%	-58%	-45%
			. / •						. ,.									,,,		

Source: Company reports and Ascendiant Capital Markets estimates.



RedHill Biopharma Ltd.

Balance Sheet (\$ mils)	Mar-19	Jun-19	Sep-19	Dec-19	Mar-20	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4E	Q1E	Q2E	Q3E	Q4E
Assets																
Cash and cash equivalents	23.0	9.0	11.6	29.0	81.6	22.3	26.2	29.3	76.0	51.8	23.3	23.2	16.2	(0.4)	(14.7)	(23.8)
Short term investments	6.1	9.4	3.3	10.3	7.1	6.2	6.2	0.0	0.0	3.5	12.0	12.0	0.0	0.0	0.0	0.0
Financial assets	16.4	16.5	10.7	8.5	6.2	4.5	2.4	0.5				0.0	0.0	0.0	0.0	0.0
Account receivables	1.4	1.0	0.9	1.2	1.7	18.6	12.4	28.7	23.3	30.1	30.0	30.0	30.0	30.0	30.0	30.0
Inventory	1.3	1.8	2.0	1.9	2.8	4.8	5.1	6.5	9.3	8.8	13.1	13.1	13.1	13.1	13.1	13.1
Prepaid expenses and other	1.2	2.3	2.3	2.2	1.6	4.9	4.6	5.5	4.1	4.3	4.7	4.7	4.7	4.7	4.7	4.7
Total current assets	49.5	40.0	30.8	53.2	101.0	61.1	57.0	70.5	112.7	98.5	83.1	83.1	64.0	47.4	33.2	24.1
Property and equipment, net	0.1	0.3	0.2	0.2	0.4	0.3	0.5	0.5	0.6	0.5	0.5	0.6	0.7	0.8	0.9	1.0
Restricted cash	0.1	0.1	0.2	0.2	20.1	20.2	16.2	16.2	16.2	16.2	16.2	16.2	16.2	16.2	16.2	16.2
Other	3.0	4.0	3.7	3.6	6.1	5.2	5.4	5.2	4.7	4.3	4.2	4.2	4.2	4.2	4.2	4.2
Goodwill and intangibles	5.3	5.3	5.3	16.9	15.9	79.5	90.0	87.9	86.1	84.2	82.4	82.4	82.4	82.4	82.4	82.4
Total assets	58.1	49.7	40.2	74.1	143.5	166.4	169.0	180.2	220.1	203.7	186.3	186.4	167.4	151.0	136.8	127.8
Liabilities and stockholders' equity																
Accounts payable and accrued exper	12.1	14.1	13.9	9.3	17.3	35.9	31.7	37.3	33.6	38.2	37.6	37.6	37.6	37.6	37.6	37.6
Allowance for deductions from reven	Je			1.3				18.3	22.7	26.1	28.4	28.4	28.4	28.4	28.4	28.4
Intangible payable								17.5	10.3	14.9	15.7	15.7	15.7	15.7	15.7	15.7
Short term debt												0.0	0.0	0.0	0.0	0.0
Total current liabilities	12.1	14.1	13.9	10.6	17.3	35.9	31.7	73.2	66.6	79.2	81.7	81.7	81.7	81.7	81.7	81.7
Other long term liabilities	4.2	3.7	3.5	3.5	4.3	16.7	28.3	11.8	17.9	11.8	9.6	9.6	9.6	9.6	9.6	9.6
Long term debt					78.2	<u>79.2</u>	80.3	<u>81.4</u>	<u>82.5</u>	83.2	83.5	<u>83.5</u>	<u>83.5</u>	83.5	83.5	83.5
Total other liabilities	4.2	3.7	3.5	3.5	82.5	95.9	108.6	93.1	100.5	94.9	93.1	93.1	93.1	93.1	93.1	93.1
Common stock	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.1	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
Additional paid-in capital	219.5	219.5	219.5	267.4	267.4	273.7	284.8	293.1	354.1	354.4	355.6	355.6	355.6	355.6	355.6	355.6
Retained earnings	(178.4)	(188.4)	(197.4)	(208.4)	(224.7)	(240.1)	(257.1)	(280.3)	(302.3)	(326.2)	(345.4)	(365.3)	(384.3)	(400.7)	(414.9)	(423.9)
Warrants												0.0	0.0	0.0	0.0	0.0
Accumulated other comprehensive in	come											0.0	0.0	0.0	0.0	0.0
Other												<u>20.0</u>	<u>20.0</u>	<u>20.0</u>	20.0	20.0
Total stockholders' equity	41.9	31.9	22.9	60.0	43.6	34.6	28.7	13.9	53.0	29.6	11.5	11.6	(7.4)	(23.8)	(38.0)	(47.0)
Total stockholders' equity and liabili	58.1	49.7	40.2	74.1	143.5	166.4	169.0	180.2	220.1	203.7	186.3	186.4	167.4	151.0	136.8	127.8
<u> </u>					•								•			
Balance Sheet Drivers																
	Mar-19	Jun-19	Sep-19	Dec-19	Mar-20	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22
	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4E	Q1E	Q2E	Q3E	Q4E
Book & Cash Value (per share)																
Book Value per Share (diluted)	\$1.48	\$1.12	\$0.81	\$1.84	\$1.24	\$0.97	\$0.77	\$0.37	\$1.23	\$0.63	\$0.25	\$0.23	-\$0.14	-\$0.45	-\$0.71	-\$0.88
Cash per Share (diluted)	\$1.03	\$0.65	\$0.53	\$1.21	\$2.52	\$0.79	\$0.87	\$0.79		\$1.19	\$0.75	\$0.70	\$0.30	-\$0.01	-\$0.28	-\$0.45
Net cash per Share (diluted) Source: Company reports and Ascendia	\$1.03	\$0.65	\$0.53	\$1.21	\$0.30	-\$1.42	-\$1.28	-\$1.40	-\$0.15	-\$0.60	-\$1.03	-\$0.97	-\$1.27	-\$1.58	-\$1.85	-\$2.01

Book & Cash Value (per share)														
Book Value per Share (diluted)	\$1.48	\$1.12	\$0.81	\$1.84	\$1.24	\$0.97	\$0.77	\$0.37	\$1.23	\$0.63	\$0.25	\$0.23	-\$0.14	-\$0.45
Cash per Share (diluted)	\$1.03	\$0.65	\$0.53	\$1.21	\$2.52	\$0.79	\$0.87	\$0.79	\$1.77	\$1.19	\$0.75	\$0.70	\$0.30	-\$0.01
Net cash per Share (diluted)	\$1.03	\$0.65	\$0.53	\$1.21	\$0.30	-\$1.42	-\$1.28	-\$1.40	-\$0.15	-\$0.60	-\$1.03	-\$0.97	-\$1.27	-\$1.58
Source: Company reports and Ascendia	nt Capital M	larkets est	imates											




ash Flow Statement (\$ mils)	Mar-19	Jun-19	Sep-19	Dec-19	2019	Mar-20	Jun-20	Sep-20	Dec-20	2020	Mar-21	Jun-21	Sep-21	Dec-21	2021	Mar-22	Jun-22	Sep-22	Dec-22	202
iscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-I
Cash flow from operating activities																				
Net income	(9,9)	(10.9)	(9.8)	(11.7)	(42.3)	(17.2)	(16.0)	(18.6)	(24.3)	(76.2)	(22.9)	(29.1)	(21.4)	(19.9)	(93.3)	(19.0)	(16.4)	(14.2)	(9.0)	(58
Stock comp	0.6	0.9	0.8	0.7	3.0	0.8	0.6	1.7	(24.3)	4.2	0.9	5.3	2.2	0.5	(33.3) 8.8	0.5	0.5	0.5	0.5	(00
Depreciation and amortization	0.0	0.3	0.3	0.3	1.0	0.8	0.0	0.5	0.5	4.2	0.5	0.5	0.5	0.1	1.6	0.1	0.3	0.3	0.3	
Amortization	0.2	0.2	0.5	0.3	0.2	1.1	1.8	2.1	2.1	7.0	1.8	1.8	1.8	0.1	5.5	0.1	0.1	0.1	0.1	
Financial assets gains/losses	0.9	(1.3)	(0.0)	0.2	(0.2)	0.1	1.0	2.1	(0,1)	0.0	1.0	1.0	1.0		0.0					
Bank deposit revaluation	(0.0)	(0.1)	0.1	(0.0)	(0.0)	0.1			(0.1)	0.0					0.0					
F/X gains/losses	(0.0)	(0.0)	0.1	(0.1)	(0.0)	(0.2)	(0.0)	0.0	0.4	0.0	0.0	0.0	0.0		0.1					
Debt amortization		(0.0)	0.1	(0.1)	0.0	0.1	(0.0)	0.0	(0.1)	0.2	0.0	0.0	0.9		0.9					
Unpaid interest					0.0	0.1	1.5	2.0	(3.6)	0.0			0.5		0.0					
Other gains/losses		0.0	(0.0)	0.1	0.1		1.5	2.0	(3.0)	0.0	0.0				0.0					
Other	(0.0)	0.0	(0.0)	(0.1)	(0.1)				6.0	6.0	2.6	1.2		(0.5)	3.4	(0.5)	(0.5)	(0.5)	(0.5)	
Changes in operating assets and liabiliti				(0.1)	(0.1)				6.0	0.0	2.0	1.2		(0.5)	3.4	(0.5)	(0.5)	(0.5)	(0.5)	
Account receivables	(0.5)	0.5	0.1	(0.4)	(0.3)	(0.5)	(16.9)	6.1	(16.2)	(27.4)	5.3	(6.8)	0.1		(1.4)					
Inventory	(0.5)	(0.5)	(0.2)	0.1	(0.3)	(0.3)	(10.3)	(0.4)	(10.2)	(27.4)	(2.7)	0.5	(4.4)		(6.6)					
,	0.6	(0.5)	(0.2)	0.1	(0.4)	0.6	(2.0)	0.4)	(1.4)		1 N N	(0.2)		0.0	0.8	0.0	0.0	0.0	0.0	
Prepaid expenses Accounts payable and accrued exp	1.1	0.3	0.1	(0.6)	0.9	(1.0)	(3.3)	1.3	24.3	(3.3) 26.7	1.4 (3.7)	4.5	(0.4) (0.6)	0.0	0.8	0.0	0.0	0.0	0.0	
Other liabilities	(0,1)	1.5	(0.3)	(0.6)	(1.5)	6.0	16.7	(4.2)	24.3 (1.5)	17.1	4.3	3.4	2.3	0.0	10.2	0.0	0.0	0.0	0.0	
						_													(0.0)	
Net cash (used in) provided by oper	(7.5)	(10.5)	(8.9)	(13.9)	(40.7)	(10.6)	(15.0)	(9.2)	(13.8)	(48.6)	(12.3)	(18.9)	(19.0)	(19.8)	(70.0)	(18.9)	(16.3)	(14.1)	(8.9)	(5
Cash flow from investing activities																				
Purchases of property and equipmen	(0.0)	(0.1)	(0.0)	(0.0)	(0.2)	(0.2)	(0.0)	(0.2)	0.0	(0.4)	(0.1)	(0.0)	(0.0)	(0.2)	(0.3)	(0.2)	(0.2)	(0.2)	(0.2)	
Purchases of short-term investments	1.7	(3.2)	6.0	0.9	5.4	3.2	1.0	2.1	3.9	10.2		(3.5)	(8.5)	0.0	(12.0)	12.0	0.0	0.0	0.0	1
Acquisitions					0.0	(1.2)	(52.5)	(0.7)	1.1	(53.4)					0.0					
Other		(0.1)	5.7	(5.7)	(0.0)	2.2	1.7		4.0	7.9	0.5				0.5					
let cash used in investing activities	1.7	(3.4)	11.7	(4.9)	5.2	4.0	(49.8)	1.2	9.0	(35.6)	0.4	(3.5)	(8.5)	(0.2)	(11.8)	11.8	(0.2)	(0.2)	(0.2)	1
han the second																				
cash flow from financing activities	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	=0.0	(0.5)	(0.0)		70.5	(a. 1)				(0.0)	0.0				
Issuance of debt	(0.2)	(0.2)	(0.2)	(0.2)	(0.8)	79.3	(0.5)	(0.8)	(1.6)	76.5	(0.4)		0.1	0.0	(0.3)	0.0	0.0	0.0	0.0	
Issuance of stock				36.3	36.3		6.4	9.1	8.4	23.9	57.9	0.3			58.2					
Proceeds from stock option exercises				0.0	0.0			0.1	(0.0)	0.1	3.2	0.1	0.7		4.0					
Dividends					0.0	(00.0)				0.0	60	(0.0)			0.0					
Other					<u>0.0</u>	<u>(20.3)</u>	<u>(0.4)</u>	3.6	<u>1.1</u>	<u>(16.0)</u>	<u>(2.1)</u>	<u>(2.2)</u>	<u>(1.7)</u>	<u>20.0</u>	<u>14.0</u>					
Cash provided by (used in) financing	(0.2)	(0.2)	(0.2)	36.1	35.5	59.1	5.5	12.0	7.9	84.4	58.7	(1.8)	(1.0)	20.0	75.9	0.0	0.0	0.0	0.0	
ffect of exchange rate on cash	0.0	0.0		0.1	0.1	0.1	0.0	(0.0)	0.0	0.1	(0.1)	0.0	(0.0)		(0.1)					
let increase (decrease) in cash and	(6.0)	(14.0)	2.6	17.4	0.0	52.6	(59.3)	3.9	3.1	0.3	46.7	(24.2)	(28.6)	(0.0)	(6.1)	(7.1)	(16.5)	(14.3)	(9.1)	(4
Beginning cash and equivalents	29.0	23.0	9.0	11.6	29.0	29.0	81.6	22.3	26.2	29.0	29.3	76.0	51.8	23.3	29.3	23.2	16.2	(0.4)	(14.7)	2
Ending cash and equivalents	23.0	9.0	11.6	29.0	29.0	81.6	22.3	26.2	29.3	29.3	76.0	51.8	23.3	23.2	23.2	16.2	(0.4)	(14.7)	(23.8)	(2



ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendiant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

RedHill Biopharma Ltd.



32

• Ascendiant Capital Markets, LLC has not received compensation for advisory or investment banking services from the company in the past 12 months.

26.00

9/10/2021 B

IMPORTANT DISCLOSURES

This report has been distributed by Ascendiant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendiant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered



companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendiant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendiant Capital Markets, LLC.

Risks & Considerations

Risks to attainment of our share price target include failure of product to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approval, failure to obtain suitable reimbursement, competition, and changing macroeconomic factors.

Ascendiant Capital Markets, LLC Rating System

- BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.
- HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.
- SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendiant Capital Markets, LLC Rating System

Prior to January 31, 2014, ASCM used the following rating system:

Strong Buy: We expect the stock to provide a total return of 30% or more wit	hin a 12-month period.
---	------------------------

- **Buy:** We expect the stock to provide a total return of between 10% and 30% within a 12-month period.
- Neutral: We expect the stock to provide a total return of between minus 10% and plus 10% within a 12-month period.
- Sell: We expect the stock to provide a total return of minus 10% or worse within a 12-month period.
- **Speculative Buy:** This rating is reserved for companies we believe have tremendous potential, but whose stocks are illiquid or whose equity market capitalizations are very small, often in the definition of a nano cap (below \$50 million in market cap). In general, for stocks ranked in this category, we expect the stock to provide a total return of 50% or more within a 12-month period. However, because of the illiquid nature of the stock's trading and/or the nano cap nature of the investment, we caution that these investments may not be suitable for all parties.

Total return is defined as price appreciation plus dividend yield.



			Investment Banking Services Past 12 months						
Rating	Count	Percent	Count	Percent					
Buy	41	98%	14	34%					
Hold	0	0%	0	0%					
Sell	1	2%	0	0%					
Total	42	100%	14	33%					

Ascendiant Capital Markets, LLC Distribution of Investment Ratings (as of October 15, 2021)

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendiant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendiant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendiant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendiant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendiant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendiant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendiant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendiant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendiant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.